Divis Laboratories Ltd vs Q-Line Biotech Ltd

A side-by-side comparison of Divis Laboratories Ltd (DIVISLAB) and Q-Line Biotech Ltd (QLINE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divis Laboratories Ltd leads DIVISLAB vs QLINE on 8 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

75.78
P/E ratio
14.94
11.59
P/B ratio
2.65
0.41%
Dividend yield
0.00%
₹96.73
EPS
₹34.24

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
25.90%
22.00%
Return on capital
22.00%
33.00%
EBITDA margin
29.00%
24.32%
Net margin
16.37%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
23.18%
12.10%
Profit CAGR (3Y)
20.51%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.93L Cr
Market cap
₹1,316 Cr
₹10,560 Cr
Revenue
₹342 Cr
₹2,568 Cr
Net profit
₹56 Cr
0.00
Debt / equity
0.75
Divis Laboratories Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 11.5 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Q-Line Biotech Ltd
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%"]
  • ["Debtor days have increased from 92.7 to 134 days."]
Divis Laboratories Ltd full analysis Q-Line Biotech Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.